Next Article in Journal
Binding of Immunoglobulin G to Protoporphyrin IX and Its Derivatives: Evidence the Fab Domain Recognizes the Protoporphyrin Ring
Next Article in Special Issue
Selection and Characterization of a Nanobody Biosensor of GTP-Bound RHO Activities
Previous Article in Journal
Acknowledgement to Reviewers of Antibodies in 2018
Previous Article in Special Issue
Single-Domain Antibodies and Their Formatting to Combat Viral Infections
Open AccessReview

Current Approaches and Future Perspectives for Nanobodies in Stroke Diagnostic and Therapy

1
Department of Neurology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
2
Institute of Immunology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany
*
Author to whom correspondence should be addressed.
Antibodies 2019, 8(1), 5; https://doi.org/10.3390/antib8010005
Received: 30 November 2018 / Revised: 20 December 2018 / Accepted: 27 December 2018 / Published: 3 January 2019
(This article belongs to the Special Issue Nanobody)
Antibody-based biologics are the corner stone of modern immunomodulatory therapy. Though highly effective in dampening systemic inflammatory processes, their large size and Fc-fragment mediated effects hamper crossing of the blood brain barrier (BBB). Nanobodies (Nbs) are single domain antibodies derived from llama or shark heavy-chain antibodies and represent a new generation of biologics. Due to their small size, they display excellent tissue penetration capacities and can be easily modified to adjust their vivo half-life for short-term diagnostic or long-term therapeutic purposes or to facilitate crossing of the BBB. Furthermore, owing to their characteristic binding mode, they are capable of antagonizing receptors involved in immune signaling and of neutralizing proinflammatory mediators, such as cytokines. These qualities combined make Nbs well-suited for down-modulating neuroinflammatory processes that occur in the context of brain ischemia. In this review, we summarize recent findings on Nbs in preclinical stroke models and how they can be used as diagnostic and therapeutic reagents. We further provide a perspective on the design of innovative Nb-based treatment protocols to complement and improve stroke therapy. View Full-Text
Keywords: nanobodies; ischemia; stroke; MCAO; single domain antibodies nanobodies; ischemia; stroke; MCAO; single domain antibodies
Show Figures

Figure 1

MDPI and ACS Style

Jank, L.; Pinto-Espinoza, C.; Duan, Y.; Koch-Nolte, F.; Magnus, T.; Rissiek, B. Current Approaches and Future Perspectives for Nanobodies in Stroke Diagnostic and Therapy. Antibodies 2019, 8, 5.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop